Clinical Trial Update: Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a conditioning regimen (busulfan, melphalan, and etoposide) for autologous transplantation in non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Etoposide (Etoposide)
• Melphalan (Melphalan)

Snippet

Sponsor: Soonchunhyang University Hospital | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED